RecruitingRecruiting
Predictors of Poor Prognosis in HFpEF
NCT06844032 · National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Clinical, Hemodynamic and Neurohumoral Predictors of Poor Prognosis in Heart Failure With Preserved Ejection Fraction
About this study
Heart failure with preserved ejection fraction (HFpEF) is a serious condition with an unfavorable prognosis.
The investigators aimed to evaluate in patients with HFpEF:
* the prognostic significance of standard resting hemodynamic parameters compared to key cardiac reserves;
* the prognostic significance of clinical parameters (sex, age, NYHA class, extra-cardiac diseases, therapy);
* the prognostic significance of biological markers of hemodynamic stress and biomarkers of inflammation and fibrosis;
* to identify independent predictors of adverse prognosis of HFpEF.
Eligibility criteria
Inclusion Criteria:
1. Signed and data informed consent;
2. New York Heart Association (NYHA) class II-III heart failure;
3. Left ventricular ejection fraction \> 50%;
4. Elevated LV filling pressures assessed by echocardiography at rest or at peak exercise.
Exclusion Criteria:
1. Evidence of myocardial ischemia during stress echocardiography;
2. Significant lesions of the main coronary arteries;
3. Genetic forms of HFpEF (HCM, amyloidosis, Fabry disease, glycogen storage diseases etc.);
4. Peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, viral myocarditis, isolated right-sided HF without left-sided structural disease, constrictive pericarditis, significant pericardial effusion;
5. Significant lung disease (severe lung disease requiring home oxygen or chronic oral steroid therapy);
6. Primary pulmonary artery hypertension;
7. Significant left-sided structural valve disease;
8. Anemia (Hb \< 100 g/L);
9. Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (CKD-EPI);
10. Non-cardiac conditions that complicate/exclude participation in the study;
11. Exacerbation of heart failure less than 3 months prior to study entry.
Study design
Enrollment target: 500 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-01-31
Estimated completion: 2026-12-31
Last updated: 2026-04-17
Primary outcomes
- • Hospitalization for exacerbation of HF (From enrollment to August 2026)
- • All-cause mortality (From enrollment to August 2026)
Sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · other_gov
Contacts & investigators
ContactArtem G Ovchinnikov, MD, PhD, DSc · contact · artcardio@mail.ru · +74954146612
All locations (1)
Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. of the Ministry of Health of the Russian FederationRecruiting
Moscow, Russia